ヘッジファンド クロムウェルホールディングズは,株式が656. 8%上昇したため,ゲンマブでその賭けを強化した. Hedge fund Cromwell Holdings boosted its stake in Genmab, as the company's stock soared 656.8%.

ヘッジファンド Cromwell Holdings LLCはデンマークの抗体治療会社 Genmab A/Sの株式を大幅に増やし,第4四半期に2,496株をさらに取得し,総株数を2,876株に押し上げました. Hedge fund Cromwell Holdings LLC significantly increased its stake in Danish antibody therapeutics company Genmab A/S, acquiring 2,496 more shares in the fourth quarter, pushing its total to 2,876 shares. ゲンマブの株式は同期間に656.8%上昇し,同社は収益の期待に打ち勝ち,507 EPS対0.28の合意を報告した. Genmab's stock saw a 656.8% rise in the same period, and the company beat earnings expectations, reporting $0.57 EPS versus the $0.28 consensus. 組織の所有権は7. 7%で,株式は4.2.17の目標価格を掲げる"モデレートバイヤー"の格付けがある. Institutional ownership stands at 7.07%, and the stock has a "Moderate Buy" rating with a $42.17 target price.